Featured Research

from universities, journals, and other organizations

"Crossover" Drug Effective For Restless Legs Syndrome

Date:
November 26, 2002
Source:
American Academy Of Neurology
Summary:
An anticonvulsant drug typically used to control seizures and neuropathic pain may reduce symptoms among those who suffer from restless legs syndrome (RLS), a movement disorder that affects up to 10 percent of the population.

ST. PAUL, MN – An anticonvulsant drug typically used to control seizures and neuropathic pain may reduce symptoms among those who suffer from restless legs syndrome (RLS), a movement disorder that affects up to 10 percent of the population. A study published in the November 26 issue of Neurology, journal of the American Academy of Neurology, concludes, "Gabapentin may be a potent agent for treatment of even severe RLS, without the disadvantages of long-term complications of previously favored treatments," according to study author Diego Garcia-Borreguero, MD, of the Fundacion Jimenez Díaz in Madrid, Spain.

RLS is characterized by: an urge to move the legs, generally accompanied by unpleasant sensations; an increase of symptoms during rest and a partial, temporary relief of symptoms through activity; and worsening of symptoms in the evening or at night. Symptoms tend to progress with age. RLS is usually treated with dopaminergic drugs, such as those used with Parkinson's disease patients. However, the side effects and likelihood of long-term complications have driven the search for RLS treatment options.

Researchers performed a double-blind study of the effectiveness of gabapentin with 24 patients with RLS, eight men and 16 women. None of the patients had been treated previously with either gabapentin or dopaminergic medications, and any other medications were discontinued at least two weeks before the study began. Patients were randomized and assigned to receive either gabapentin or placebo in the first of two six-week intervals, with a one-week "washout period" between alternating treatments. Physical and neurological examinations were performed at baseline, at the first visit (neurological examination only), and at the end of each treatment period. Patients also completed hourly symptom severity ratings.

Using sleep studies as well as an RLS severity rating scale, a sleep questionnaire, and patients' own perception of clinical symptom change, researchers found treatment with gabapentin improved (reduced) RLS symptoms in the study group. Sleep studies also showed a marked reduction in leg movements, as well as an overall improvement of total sleep time and sleep quality during treatment with gabapentin. "Our study shows dramatic therapeutic effects of gabapentin in RLS under controlled conditions," concludes Garcia Borreguero. "Additional long-term studies are warranted to confirm our outcomes and examine gabapentin tolerance during chronic treatment."

###

The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research.

For more information about the American Academy of Neurology, visit its website at http://www.aan.com.


Story Source:

The above story is based on materials provided by American Academy Of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. ScienceDaily, 26 November 2002. <www.sciencedaily.com/releases/2002/11/021126073328.htm>.
American Academy Of Neurology. (2002, November 26). "Crossover" Drug Effective For Restless Legs Syndrome. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2002/11/021126073328.htm
American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. www.sciencedaily.com/releases/2002/11/021126073328.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins